Home/ Stocks/ ELDN

Eledon Pharmaceuticals, Inc. Common Stock

ELDN XNAS

$3.69 +0.32 (+9.31%) ▲ 15-min delayed

Open

$3.46

High

$3.70

Low

$3.44

Volume

930.0K

Market Cap

$267.07M

About Eledon Pharmaceuticals, Inc. Common Stock

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 33 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-39,025,000	$-0.33
FY 2025	N/A	$-45,617,000	$-0.52
Q3 2025	$0	$-17,459,000	$-0.21
Q2 2025	$0	$-11,216,000	$-0.13

Related Market News

No specific coverage for ELDN yet. Check out our latest market news or earnings calendar.

Get ELDN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Eledon Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.